Figure 4.
Time to MRD reemergence according to posttreatment MRD status by NGS. (A) Time to MRD reemergence, according to MRD status (detectable vs undetectable) in BM at the EOT, assessed by NGS. Testing for MRD reemergence was performed with 4-color FLC, in peripheral blood (PB). Fifty-one of 57 patients who had BM samples available for NGS MRD testing had serial PB FLC MRD results available in PB for this analysis. (B) Time to MRD reemergence according to NGS-MRD status (detectable vs undetectable) in PB. Twenty-six of 29 patients who had PBMC samples available had serial FLC MRD results available for this analysis. (C) Time to MRD reemergence according to NGS-MRD status (<10−6 vs ≥10−6) in BM. Of 51 patients with BM samples for NGS and serial FLC MRD in PB, 47 were included in this analysis. Four were excluded as they had U-MRD in BM by NGS, but sensitivity did not reach 10−6. (D) Time to MRD reemergence by NGS-MRD status (<10−6 vs ≥10−6) in PBMC. Of 26 patients with PBMC samples for NGS and serial FLC MRD performed in PB, 18 were included in this analysis. Eight were excluded as they had U-MRD in PBMC by NGS, but sensitivity did not reach 10−6. (E) Time to progression (TTP) and time to next treatment (TTNT) after reemergence of PB MRD. Thirty patients had reemergence of MRD by FLC during follow-up and were included in this analysis.